Antibiotic Therapy Begins
A broad-spectrum antibiotic enters the gut to fight infection.
- 5–35%: AAD incidence (of antibiotic courses)
- 3: Highest-risk classes (clindamycin, penicillins, cephalosporins)
- ~1,000: Gut species affected (resident bacterial taxa)
- 2 mo: Onset window (up to 8 weeks post-course)
Why antibiotics reach the gut
Oral antibiotics pass through the entire intestinal tract.
Broad-spectrum collateral damage
Broad drugs cannot distinguish pathogens from helpful flora.
Course length matters
Longer courses cause deeper, longer-lasting flora disruption.
Flora Disruption
Beneficial bacteria die alongside the antibiotic's intended targets.
- up to 30%: Diversity loss (after one course)
- 6–12 mo: Recovery time (for full flora rebound)
- ↓ sharply: SCFA output (short-chain fatty acids)
- ↓: Colonization resistance (natural pathogen barrier weakens)
Commensals are collateral casualties
Susceptible commensal strains die within days of dosing.
Barrier function weakens
Fewer bacteria means a thinner protective mucus layer.
Niches open up
Dead bacteria leave empty attachment sites behind.
Opportunistic Overgrowth Risk
Disrupted flora lets pathogens like C. difficile move in.
- ~500k: C. diff infections/yr (US) (mostly antibiotic-linked)
- ~20%: Recurrence rate (after first episode)
- months: Spore persistence (on surfaces and in gut)
- ~5%: Severe case mortality (of C. diff infections)
Empty niches, easy entry
Pathogen spores germinate fastest where flora is thin.
Toxin-driven diarrhea
Overgrown pathogens release toxins that damage gut lining.
A preventable window
This risk window is exactly where prevention helps most.
Probiotic Co-Administration
Evidence-based probiotic strains are taken during the antibiotic course.
- 2–3: Strains with evidence (Lactobacillus, Saccharomyces)
- ~50%: Relative risk reduction (meta-analyses of AAD trials)
- same day: Best timing (as first antibiotic dose)
- 2 hrs: Dosing gap advised (between antibiotic and probiotic)
Competitive exclusion
Probiotic strains occupy niches before pathogens can.
Strain specificity matters
Only certain studied strains show real clinical benefit.
Timing affects survival
Spacing doses helps probiotic organisms survive the antibiotic.
Reduced Diarrhea Risk
Co-administration measurably lowers antibiotic-associated diarrhea incidence.
- ~20%: AAD risk without probiotic (typical course baseline)
- ~8–10%: AAD risk with probiotic (evidence-based co-dosing)
- ~10–15: NNT to prevent one case (number needed to treat)
- ~60%: C. diff risk reduction (select high-quality trials)
Flora rebounds faster
Co-administered gut communities recover diversity sooner.
Fewer opportunist blooms
Occupied niches mean fewer pathogen overgrowth events.
A simple, low-cost habit
One added daily dose meaningfully shifts patient outcomes.